Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Xie, Qian; Zheng, Hanrui; Li, Qiu.
Affiliation
  • Xie Q; Ward of General Practice/International Medical Center, West China Hospital, Sichuan University, Chengdu, China.
  • Zheng H; Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
  • Li Q; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Breast Care (Basel) ; 17(3): 237-243, 2022 Jun.
Article in En | MEDLINE | ID: mdl-35957949
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Breast Care (Basel) Year: 2022 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Breast Care (Basel) Year: 2022 Document type: Article Affiliation country: China